New class of antivirals in testing against SARS-CoV-2 virus
Main content start
(August 2020)
Annelise Barron and collaborators have developed a new class of antivirals, based on peptoid mimics of natural human antiviral peptides, which already have demonstrated activity against Herpes Simplex Virus-1 and Hepatitis C Virus. A set of these antiviral peptoids will be tested against the SARS-CoV-2 virus, in vitro and in vivo, at NYU’s School of Medicine, beginning the week of March 30th.